Table 2.

Incidence rates of events during follow-up per 100 person-yr of patients prescribed raltegravir and other third-line drugs for salvage regimens.

Events during follow-up	Eligible population (n = 168; 178.05 p-y)		Matched subset (n = 90; 98.06 p-y)		IRR (95%CI)*; P†
	Raltegravir (n = 123, 129.54 p-y)	Other drugs (n = 45, 48.51 p-y)	Raltegravir (n = 45, 49.55 p-y)	Other drugs (n = 45, 48.51 p-y)
Drug toxicity	0.77	2.06	0.00	2.06	−, .49
Treatment interruption	12.35	0.00	8.07	0.00	−, .06
Virologic failure	2.32	4.12	2.02	4.12	.49 (.04–5.40), .61
Loss of follow-up	3.86	4.12	6.05	4.12	1.47 (.25–8.79), .70
Death	4.63	6.18	4.04	6.18	.65 (.11–3.91), .67

CI = confidence interval, p-y = person-year.

^*IRR (incidence rate ratio) and 95% CI for rates of each event by salvage regimen were calculated by Poisson regression, where other drugs were considered as comparators.

^†Wald test P value.